Opinion ID: 4766018
Heading Depth: 3
Heading Rank: 1

Heading: A method for reducing incidence of or treat-

Text: ing at least one vasomotor symptom in an individ- ual, comprising administering to the individual an effective amount of an anti-CGRP antagonist antibody, wherein said anti-CGRP antagonist antibody is a human monoclonal antibody or a humanized monoclonal antibody. ’045 patent, col. 99 ll. 2–7. 1. A method for treating headache in an indi- vidual, comprising: administering to the individual an effective amount of a humanized monoclonal anti- Calcitonin Gene-Related Peptide (CGRP) antagonist antibody, comprising: two human IgG heavy chains, each heavy chain comprising three complementarity determining regions (CDRs) and four framework regions, wherein portions of the two heavy chains together form an Fc re- gion; and two light chains, each light chain compris- ing three CDRs and four framework re- gions; wherein the CDRs impart to the antibody specific binding to a CGRP consisting of amino acid residues 1 to 37 of SEQ ID NO:15 or SEQ ID NO:43. ’907 patent, col. 103 ll. 21–35. 1. A method for treating headache in an indi- vidual, comprising: administering to the individual an effective amount of a humanized monoclonal anti- Case: 20-1876 Document: 50 Page: 5 Filed: 08/16/2021 ELI LILLY AND COMPANY v. TEVA PHARMACEUTICALS 5 Calcitonin Gene-Related Peptide (CGRP) antagonist antibody, comprising: two human IgG heavy chains, each heavy chain comprising three complementarity determining regions (CDRs) and four framework regions, wherein portions of the two heavy chains together form an Fc re- gion; and two light chains, each light chain compris- ing three CDRs and four framework re- gions; wherein the CDRs impart to the antibody specific binding to a CGRP consisting of amino acid residues 1 to 37 of SEQ ID NO:15 or SEQ ID NO: 43, and wherein the antibody binds to the CGRP with a binding affinity (KD) of about 10 nM or less as meas- ured by surface plasmon resonance at 37o C. ’908 patent, col. 99 l. 55–col. 100 l. 57. The differences between these claims have not been argued as significant to these appeals.